SIM0613 in people with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 1, open-label, multicenter study designed to determine safety, tolerability, preliminary efficacy, and pharmacokinetics/pharmacodynamics of SIM0613 in adults with locally advanced or metastatic solid tumors. The trial uses a dose-escalation part to identify appropriate dose levels, followed by a dose-expansion part to further explore activity at the selected dose. Eligible participants have measurable disease, have progressed on or are intolerant to standard therapies, and meet organ-function and other criteria. Tissue samples may be collected for biomarker analyses, particularly during Part 1, to support correlative assessments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent (ICF) is obtained prior to any of the specified procedures required for the study
2. ≥18 years of age
3. Histologically or cytologically confirmed locally advanced/metastatic solid tumors
4. Have at least one measurable disease per RECIST Version 1.1 criteria
5. Have experienced disease progression on/after at least one accessible standard therapy, or are intolerant to standard therapy, or are not suitable for standard therapy, or for whom clinical trial of the investigational drug serves as standard treatment
6. Life expectancy of ≥12 weeks
7. Have adequate organ function
8. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 3 days prior to the start of study treatment.
9. For Part 1, archival or fresh tumor tissue sample (preferably 12 with a minimum number of 10 sections) should be collected if available at Biomarker-screening or screening visit. For Part 2, it is mandatory to collect archival tumor tissue sample (preferably 12 with a minimum number of 10 sections) performed within 6 months prior to consent or fresh tumor tissue sample at Biomarker-screening or screening visit

Exclusion Criteria：

1. Any other malignancy within 2 years prior to the first dose of the study treatment except for localized cancers that are considered to have been cured and in the opinion of the Investigator present a low risk for recurrence (e.g., basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast)
2. Participants with symptomatic central nervous system (CNS) metastases, or CNS metastases requiring CNS-directed local therapy (such as radiotherapy or surgery), or CNS metastases requiring corticosteroids therapy within 2 weeks of first dose of study treatment.
3. History of bowel obstruction within 3 months prior to the first dose of study treatment.
4. Known psychiatric disorder or drug abuse that would interfere the study requirements
5. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring drainage or medical intervention within 4 weeks before the first dose of study treatment
6. Any active infection requires systemic treatment via intravenous infusion within 2 weeks prior to the first dose of study treatment
7. Has not recovered (i.e., to Grade 1 or to baseline) from previous anticancer therapy-induced AEs.
8. Participant is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of first dose of SIM0613.
9. Major surgery within 2 weeks of receiving the first dose of study treatment (minor procedures such as mediastinoscopy, insertion of a central venous access device, insertion of a feeding tube, needle biopsy and percutaneous nephrostomy are not considered major surgery)
10. Prior exposure to topoisomerase I (TOP-I) inhibitor inhibitor-based antibody-drug conjugate (ADC) therapies or LRRC15-targeted therapies.
11. Use of any live vaccine therapy within 4 weeks prior to the first dose of study treatment
12. Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS)
13. Active hepatitis B (HBsAg or HBcAb positive）
14. History of allogeneic organ transplantation or graft-versus-host disease
15. Known hypersensitivity to study drug or any of the excipients
16. Participant is pregnant or breastfeeding
17. Other conditions that researchers consider inappropriate for inclusion.

Where it's running

• Tianjin Medical University Cancer Institute and Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Qiuping Huang, Master
• Email: huangqiuping@zaiming.com
• Phone: +86 021-58831288

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing how well different doses of BI 3819026 can be tolerated alone and with ezabenlimab in advanced cancer

  This study tests whether varying doses of BI 3819026 can be tolerated by adults with advanced solid cancers, both by itself and in combination with ezabenlimab.

  Recruiting at 8 sites Phase 1 Boehringer Ingelheim · New Haven, Connecticut and 8 other locations · NCT07607678

• Phase I testing of SIM0609 in adults with advanced or metastatic solid tumors

  This trial tests SIM0609 to see if it is safe, tolerated, and can shrink tumors in adults with locally advanced or metastatic solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Beijing and 5 other locations · NCT07265921

• Personalized KXV01 TCR Lentinvivo Injection for Advanced Solid Tumors

  A first-in-human, single-arm study tests a KXV01 TCR lentiviral treatment given in vivo to see if it is safe and tolerable for adults with advanced solid cancers that have exhausted standard therapies.

  Recruiting Phase 1 TCRx Therapeutics Co.Ltd · Hefei, Anhui · NCT07196579

• APX-343A alone or with pembrolizumab for advanced solid tumors

  This Phase 1 trial will test whether APX-343A by itself or combined with the immunotherapy pembrolizumab is safe and shows early benefit in adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 Aptabio Therapeutics, Inc. · Seongnam and 2 other locations · NCT07123415

• MHB046C injection for adults with advanced solid tumors

  This study will test whether MHB046C injections are safe and might shrink or control advanced solid tumors in adults who have no standard treatment options.

  Recruiting Phase 1/2 Minghui Pharmaceutical (Hangzhou) Ltd · Guangzhou, Guangdong · NCT06985355

• SYN818 for advanced or metastatic solid tumors

  This Phase 1 study will test oral SYN818 in adults with advanced or metastatic solid tumors, including breast, ovarian, and prostate cancers, whose standard treatments have been exhausted.

  Recruiting at 2 sites Phase 1 Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Zhengzhou, Henan and 1 other locations · NCT06666270

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.